# OrigAMI-1 (NCT05379595)

> A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05379595
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Advanced or Metastatic Colorectal Cancer
- Interventions: Amivantamab IV; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan; Amivantamab
- Enrollment: 225
- Primary outcome: Cohorts A, B, and C: Objective Response Rate (ORR)
- Primary outcome: Cohorts Ph1b-D and Ph1b-E: Number of Participants with Dose-limiting Toxicity (DLT)
- Primary outcome: Cohorts Ph1b-D and Ph1b-E: Number of Participants with DLT by Severity
- Primary outcome: Cohorts D and E: Number of Participants with Adverse Events (AE)
- Primary outcome: Cohorts D and E: Number of Participants with Laboratory Values Abnormalities
- Primary outcome: Cohorts D and E: Number of Participants with Vital Signs Abnormalities
- Primary outcome: Cohorts F: Number of Participants with Adverse Events (AE)
- Primary outcome: Cohorts F: Number of Participants with Laboratory Values Abnormalities
- Primary outcome: Cohorts F: Number of Participants with Vital Signs Abnormalities

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 12
- YouTube: 7
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=origami-1-nct05379595

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05379595", "email": "<work email>"}; the inbox owner confirms by the emailed link.